Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 (known as HER2-positive) or not (HER2-negative). Typically, patients with HER2-positive disease have a worse prognosis. Trastuzumab is a selective treatment that targets the HER2 pathway. The available evidence supporting trastuzumab regimens mostly relies upon surrogate endpoints and, although the efficacy results seem to support its use, other uncertainties have been raised about its net benefit in relation to transient cardiac toxicity and a long-term increased risk of metastasis to the central nervous system.
Trastuzumab-containing regimens for metastatic breast cancer / S. Balduzzi, S. Mantarro, V. Guarneri, L. Tagliabue, V. Pistotti, L. Moja, R. D'Amico. - In: COCHRANE DATABASE OF SYSTEMATIC REVIEWS. - ISSN 1469-493X. - 2014:6(2014 Jun), pp. CD006242.1-CD006242.80.
Trastuzumab-containing regimens for metastatic breast cancer
L. Tagliabue;L. MojaPenultimo
;
2014
Abstract
Patients with breast cancer are classified as having cells that over-express the human epidermal growth factor receptor 2 (known as HER2-positive) or not (HER2-negative). Typically, patients with HER2-positive disease have a worse prognosis. Trastuzumab is a selective treatment that targets the HER2 pathway. The available evidence supporting trastuzumab regimens mostly relies upon surrogate endpoints and, although the efficacy results seem to support its use, other uncertainties have been raised about its net benefit in relation to transient cardiac toxicity and a long-term increased risk of metastasis to the central nervous system.File | Dimensione | Formato | |
---|---|---|---|
CD006242.pdf
Open Access dal 25/06/2015
Tipologia:
Publisher's version/PDF
Dimensione
901.84 kB
Formato
Adobe PDF
|
901.84 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.